Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)
Authors
Keywords
-
Journal
HEPATOLOGY
Volume 63, Issue 5, Pages 1430-1441
Publisher
Wiley
Online
2016-01-29
DOI
10.1002/hep.28473
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C
- (2015) Ranka Vukotic et al. DIGESTIVE AND LIVER DISEASE
- Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection
- (2015) Graham R. Foster et al. GASTROENTEROLOGY
- Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
- (2015) Eric Lawitz et al. HEPATOLOGY
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
- (2015) David R. Nelson et al. HEPATOLOGY
- P0840 : Safety and effectiveness of sofosbuvir-based regimens for the treatment of hepatitis C genotype 3 and 4 infections: Interim analysis of a prospective, observational study
- (2015) S. Alqahtani et al. JOURNAL OF HEPATOLOGY
- P0867 : Efficacy evaluation of 24 week SOF + RBV in a heterogeneous, real-world population of genotype 3 HCV patients; Data from the trio network
- (2015) K. Kowdley et al. JOURNAL OF HEPATOLOGY
- EASL Recommendations on Treatment of Hepatitis C 2015
- (2015) JOURNAL OF HEPATOLOGY
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
- (2015) Graham R. Foster et al. NEW ENGLAND JOURNAL OF MEDICINE
- In VitroActivity and Resistance Profile of Dasabuvir, a Nonnucleoside Hepatitis C Virus Polymerase Inhibitor
- (2014) Warren Kati et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients
- (2013) A. H. Talal et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
- (2012) Fiona McPhee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study
- (2012) Christophe Moreno et al. JOURNAL OF HEPATOLOGY
- Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202)
- (2012) Oliver Lenz et al. JOURNAL OF HEPATOLOGY
- Hepatitis C Virus Genotypes in Clinical Specimens Tested at a National Reference Testing Laboratory in the United States
- (2011) J. J. Germer et al. JOURNAL OF CLINICAL MICROBIOLOGY
- HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis
- (2011) G. Nkontchou et al. JOURNAL OF VIRAL HEPATITIS
- Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
- (2011) Mark S. Sulkowski et al. Nature Reviews Gastroenterology & Hepatology
- Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus
- (2010) Michael J. Sofia et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
- (2010) Min Gao et al. NATURE
- Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C
- (2009) Pierre-Yves Bochud et al. JOURNAL OF HEPATOLOGY
- Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis
- (2008) A. ANDRIULLI et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission
- (2008) Muhammad Idrees et al. BMC INFECTIOUS DISEASES
- Changing HCV genotypes distribution in Poland—Relation to source and time of infection
- (2008) Slawomir Chlabicz et al. JOURNAL OF CLINICAL VIROLOGY
- Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006
- (2008) Francois Roman et al. WORLD JOURNAL OF GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started